The abstract is read at the publisher; the summary is JClub's.
Dostarlimab monotherapy in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer achieved 68% sustained clinical complete response at 12 months (cCR12, investigator review).
- Why it matters: Standard multimodal care for locally advanced rectal cancer carries substantial toxicity, and after TNT the cCR rate is only 21–41%, leaving room for more effective, less burdensome options.
- What they did: In the global AZUR-1 registrational study, adults received dostarlimab 500 mg IV every 3 weeks for 9 cycles, with cCR12 assessed at end of treatment and followed for 12 months by investigator and independent central review.
- The result: Among 144 patients with at least 12 months follow-up, 68% reached cCR12 (INV) and 76% achieved cCR12+pCR; 98% of cCR patients maintained cCR for ≥12 months, with no recurrences reported for those in cCR or pCR.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.